What Happened
On May 12, 2026, DEA Detroit issued a Public Safety Advisory warning that illicit fentanyl in the Great Lakes region is increasingly adulterated with two compounds that complicate standard overdose response: medetomidine and nitazenes.
Medetomidine is a veterinary alpha-2 adrenergic agonist in the same drug family as xylazine. It extends and deepens a fentanyl high — and produces a withdrawal syndrome that naloxone does not address. By late 2025, medetomidine was present in 25.1% of New York City opioid samples, with peaks reaching 44.1% in certain areas. Deaths attributable to medetomidine exposure in NYC: 18 in 2024, 134 in 2025. The CDC issued a Health Advisory on April 2, 2026 specifically about its spread.
Nitazenes are synthetic opioids — estimated to be 10 to 43 times more potent than fentanyl. Unlike medetomidine, they are opioids and do respond to naloxone, but may require multiple doses. The DEA has identified 22 unique nitazene compounds since 2020, with 21 now classified as Schedule I controlled substances.
Why It Matters
The convergence of these adulterants in a single sample represents a genuinely new overdose profile. A person experiencing a combined medetomidine-nitazene-fentanyl overdose will need higher naloxone doses for the nitazene component, and will still face a dangerous sedative withdrawal after opioid reversal. This is precisely the scenario that drove adoption of drug-checking services — and precisely the scenario that SAMHSA’s April 24 guidance on test strip defunding makes harder to prepare for.
First responders, harm reduction workers, and people who use drugs all benefit from knowing what’s in local supply. If you or someone you know needs help now, call SAMHSA’s helpline: 1-800-662-4357.
Sources Cited
- 01.A
- 02.A
Filed Under
trendsscience